[go: up one dir, main page]

AU6123894A - Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto - Google Patents

Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto

Info

Publication number
AU6123894A
AU6123894A AU61238/94A AU6123894A AU6123894A AU 6123894 A AU6123894 A AU 6123894A AU 61238/94 A AU61238/94 A AU 61238/94A AU 6123894 A AU6123894 A AU 6123894A AU 6123894 A AU6123894 A AU 6123894A
Authority
AU
Australia
Prior art keywords
lymphocytes
antibodies
modulation
physiological responses
responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61238/94A
Inventor
J. Fernando Bazan
Christopher C Goodnow
J. Christopher Grimaldi
Andrew Heath
Maureen C Howard
R. Michael E Parkhouse
Leopoldo Santos-Argumedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Leland Stanford Junior University
Original Assignee
Schering Corp
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Leland Stanford Junior University filed Critical Schering Corp
Publication of AU6123894A publication Critical patent/AU6123894A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU61238/94A 1993-01-29 1994-01-27 Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto Abandoned AU6123894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1090593A 1993-01-29 1993-01-29
US010905 1993-01-29
PCT/US1994/000517 WO1994017184A1 (en) 1993-01-29 1994-01-27 Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto

Publications (1)

Publication Number Publication Date
AU6123894A true AU6123894A (en) 1994-08-15

Family

ID=21747966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61238/94A Abandoned AU6123894A (en) 1993-01-29 1994-01-27 Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto

Country Status (2)

Country Link
AU (1) AU6123894A (en)
WO (1) WO1994017184A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA943348B (en) * 1993-05-21 1995-11-16 Hirano Toshio A gene encoding a polypeptide having pre-B cell growth-supporting ability
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
JPH11310596A (en) * 1998-04-28 1999-11-09 Seibutsu Bunshi Kogaku Kenkyusho:Kk Bone marrow stromal cell antigen binding protein
US7695933B2 (en) 2000-10-17 2010-04-13 Trudeau Institute, Inc. SM38 nucleic acid molecules
US6955884B2 (en) * 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
AU2003241103A1 (en) 2002-04-23 2003-11-10 Umberto Dianzani Compositions containing anti-hiv peptides and methods of use
MXPA06008700A (en) 2004-02-06 2007-01-19 Morphosys Ag Anti-cd38 human antibodies and uses therefor.
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP1716176B1 (en) * 2004-02-13 2009-10-21 Boehringer Ingelheim Pharmaceuticals, Inc. Cd38 splice variant and uses thereof
JP5225069B2 (en) 2005-03-23 2013-07-03 ゲンマブ エー／エス Antibodies against CD38 for the treatment of multiple myeloma
SG10201400973XA (en) 2005-10-12 2014-08-28 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
PT2081595T (en) 2006-09-26 2019-07-16 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
SI2580243T1 (en) 2010-06-09 2020-02-28 Genmab A/S Antibodies against human cd38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MA40608A (en) 2014-09-09 2016-03-17 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
WO2016187546A1 (en) 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SMT202100192T1 (en) 2015-11-03 2021-05-07 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP2019527678A (en) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー Treatment of IgE-mediated diseases with antibodies that specifically bind to CD38
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT53672A (en) * 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
SU1595902A1 (en) * 1988-06-30 1990-09-30 Всесоюзный онкологический научный центр АМН СССР Strain of mus musculus l hybrid cultivable cells for producing monoclonal antibodies to atigen cd38

Also Published As

Publication number Publication date
WO1994017184A1 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
AU6123894A (en) Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
AU4107396A (en) Synthetic media for blood components
AU7243194A (en) Synthetic media for blood components
AU5267190A (en) Modified antibodies
AU3688393A (en) Surgical fastener
AU4441493A (en) Lancet
AU4670293A (en) Non-invasive testing
AU7867994A (en) Hemofiltration of mediator-related diseases
AU625613B2 (en) Novel chimeric antibodies
AU4680797A (en) Preparation of substituted guanidines
AU5545694A (en) Detection of selected antigen-antibody reactions
AU6107390A (en) Use of amide complex compounds
AU6280394A (en) Ultrasonic activator
AU2467395A (en) Novel ophthalmologic uses of protein c
AU7992994A (en) Immunoassay for the dectection of human autoantibodies
AU5602394A (en) Chimeric blood coagulation proteins
AU4435689A (en) Atomisation of liquids
AU3263493A (en) Tonometer
AU6723294A (en) Use of simmondsine
AU2383288A (en) Human anti-rh(d) monoclonal antibodies
AU4033593A (en) Modulation of thrombospondin-CD36 interactions
AU4489196A (en) Novel medical use of heme products
AU5320194A (en) Insulin receptor-like protein
AU3679993A (en) Synthetic phospholipid reagent
AU4960993A (en) Instrument